BCF Technology has announced the launch of the Logiq S7 Expert ultrasound system.
BCF says the new system offers the latest in ultrasound technology and represents a significant leap forward in imaging capability.
The Logiq S7 ultrasound system includes features such as B-Flow, Elastography, Flow Quantification, Contrast Imaging, B-Steer+, 3D/4D ultrasound, Volume Imaging and Multi-Modality Imaging Display.
Nigel Perry from BCF said: "The new Logiq S7 Expert provides the highest image quality currently available in the market. With a wide range of probes available for every veterinary application. If you are looking for the ultimate in ultrasound capability then the Logiq S7 is the system for you."
For more information, visit http://www.bcftechnology.co.uk/ or call +44(0)1506 460 023.
CEVA Animal Health has confirmed its sponsorship of Stephanie Dakin, an equine veterinary PhD student at the Royal Veterinary College in London.
The four-year sponsorship, due to commence October 2008, is being run through the BBSRC Industrial CASE studentship scheme, which involves partnerships between UK-based industrial companies and eligible UK universities or research institutes, to support collaborative postgraduate research. It is the first time that CEVA, the company that recently introduced Tildren®, a treatment for equine bone disease, has undertaken such an initiative in the UK.
Stephanie is conducting her PhD on the pathogenesis and treatment of equine tendonitis. She is currently working with Professor Roger Smith, Professor of Equine Orthopaedics and Dr Jay Dudhia at the RVC, on a study to determine the efficacy of stem cells in the treatment of superficial digital flexor tendonitis in the horse.
Stephanie commented: "I am very keen to direct research in this field in order to better elucidate the mechanisms involved in tendon injury and identify therapeutic targets, such that we can improve our management and hopefully advance our ability to treat and prevent disease, thus improving the health and welfare of equine patients."
She added: "Having the opportunity to undertake this vital research, supported by the BBSRC and the industrial contribution from CEVA, is a real privilege and I hope that the findings from this study will feedback to have a direct, positive impact on clinical cases of tendonitis, in the equine and possibly the human fields."
The Waltham Equine Studies Group has published new research which highlights the effectiveness of grazing muzzles as a tool to help with weight management in ponies.
The research, which was conducted in collaboration with Dr Annette Longland of Equine and Livestock Nutrition Services (ELNS) in Wales2, also showed that longer grass can be more difficult for muzzled ponies to graze, and can cause frustration-related behaviour in some individuals.
According to Waltham, grazing muzzles have already been shown to reduce the pasture intake of ponies by around 80% by significantly reducing bite size and intake.1 Ponies fitted with grazing muzzles may spend more time engaging in foraging and eating than their non-muzzled counterparts, yet the majority either lose weight or retain their body condition. This in turn helps reduce susceptibility to obesity and related disorders, such as insulin dysregulation and laminitis.
Four mature ponies were selected for the study. Their dry matter (DM) and water-soluble carbohydrate (WSC) intakes were measured in spring, summer, and autumn pastures on four, three-hour occasions per pony per season when fitted with or without a grazing muzzle. In addition ponies, with and without muzzles, were allowed to take 10 bites of swards maintained at different heights.
When wearing grazing muzzles pasture intake was reduced by 77% during spring and summer and by 83% during the autumn. Without muzzles the ponies generally reduced the sward length by half with the first bite but when muzzled the reduction was variable and the ponies appeared to experience greater difficulty in accessing the longer versus the shorter swards.
The short (less than 10cm), upright, grass appeared to be the easiest to eat, as leaf blades and stems protruded through the holes in the muzzle. The medium and long swards proved more difficult. They bent under the pressure of the muzzle and became flattened, causing the ponies to adopt various strategies to access the grass. In some cases they pawed the ground to unearth the sward and access it through the muzzle. Alternatively they rammed the solid base of the muzzle hard onto the grass, causing it to buckle and make some blades or stems accessible. These were then yanked vigorously often causing the entire plant to be uprooted and eaten.
Water soluble carbohydrate levels in the sward were similar across the seasons although they were slightly higher in autumn. However, once muzzled the ponies’ intake of WSC wasn’t significantly different across the seasons; strengthening the evidence that the use of grazing muzzles is effective.
Clare Barfoot RNutr and the research and development manager at Spillers said: "While the frustration displayed when the muzzled ponies were on longer grass swards indicates that care should be taken to provide an accessible grass length, grazing muzzles remain an effective weight management tool. They allow turnout over large areas, increasing exercise and allow slow “trickle” feeding, to control weight gain and reduce the risk of obesity-related disorders, without significantly compromising the natural behaviour and wellbeing."
Waltham says grazing muzzles must be used with care, should be properly fitted and horses and ponies should be adapted gradually to wearing them. Group and individual behaviour should be monitored closely to observe any potential concerns caused by changes to the herd dynamics. Ensure that muzzled ponies are confident in drinking and eating through their muzzles before turning them out for prolonged periods. Muzzles must not be used continuously (not more than 10 hours per day) and total exclusion muzzles are not advised. Regular weight monitoring is recommended as some individuals can still gain weight when muzzled.
References
James Beaumont, Product Manager at Animalcare, said: “Microchipping is an essential but simple way to safeguard the welfare of the UK’s horses. Animalcare was the first company to offer a microchipping service with its identichip microchips, so we know from first-hand experience that microchipping is the most important step owners can take to ensure that lost, abandoned or stolen animals are quickly identified.
“Ensuring the welfare of their patients is a guiding principle for equine vets and we know that they are working very hard to remind owners of the need to ensure that their animals are microchipped and to then keep their contact details up to date. We hope that they will find our social media toolkit useful and that, between us, we can ensure that as many horses as possible are microchipped in time for the new law coming into force.”
To request your social media toolkit, contact your Animalcare Territory Manager or ring 01904 487687.
The Animal Health Trust has cut the first sod of a new cancer centre for animals in Suffolk.
The AHT's Cancer Centre will provide all three treatment options: surgery, chemotherapy and radiotherapy, on one site. The cancer facility is being purpose-built to treat horses, dogs and cats.
Sue Murphy, Head of Clinical Cancer Treatment at the AHT, said: "Having all three treatment options on one site means that whatever the diagnosis, we will be able to offer each and every patient the very best options for their specific case. With one in four dogs and one in six cats developing cancer at some time in their life this new centre will help many more animals - from Suffolk, East Anglia and all across the UK."
The new centre will also further research into cancer. Treating animals with all types of the disease will enable the AHT's vets and scientists to expand current knowledge about cancer. This will help with the development of new ways to diagnose and treat the disease.
Vets and scientists at the AHT already work collaboratively with cancer researchers looking at the disease in humans. There are a number of links between human and animal cancers which have already been identified. It is hoped that knowledge gained from the AHT Cancer Centre may also help in the understanding of cancer in people.
The AHT hopes the building will open in summer 2012 . It is launching an appeal to raise much needed funds to equip the centre with a linear accelerator. This piece of specialist equipment works by delivering high-energy radiation beams to break cancerous tumours down while sparing the surrounding normal tissue.
The AHT Cancer Centre will be one of only six veterinary facilities in the UK to house a linear accelerator.
Sue Murphy added: "Currently, there is no way to tell which animals will, and which animals won't, develop cancer. It could happen to any animal at any time. This new centre will give more animals a fighting chance of beating the disease, enabling them to lead long and healthy lives. The fact that treatments developed to benefit our pets may also lead to improvements in the prevention and treatment of cancer in humans makes this centre all the more important.
"I would urge you to donate whatever you can to help equip the centre. Your donation, however large or small, will help many more animals beat cancer and it may also help in the fight against cancer in people."
If you would like to make a donation to the AHT Cancer Centre please visit www.aht.org.uk or telephone 01638 555648.
Alternatively you can make a £5 donation by textingVETS24 £5 to 70070
Novartis Animal Health has announced that it will begin marketing and distributing Adequan Equine in the UK from January 2011.
According to the company, Adequan Equine offers equine veterinarians a proven intramuscular treatment option for equine degenerative joint disease, also known as non-infectious arthritis or osteoarthritis. The product is licensed in the UK for the treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital flexor tendonitis. This is a critical treatment area since equine degenerative joint disease is estimated to cause up to one-third of all equine lameness cases1. It most commonly affects the hocks and coffin joints with the most severe effects on the high-motion knee and fetlock joints.
Esther Rawlinson MRCVS, Global Technical Services Manager for the Novartis Animal Health Companion Animal Business in the Therapeutics & Equine areas said: "Adequan Equine is a leading joint treatment for horses and is widely used by veterinarians in the equine sport industry. Adequan Equine reduces pain and lameness in horses while at the same time stimulating cartilage repair.
Adequan Equine 100mg/ml solution contains polysulphated glycosaminoglycan for intramuscular injection. It is a chondroprotective, meaning it inhibits the breakdown of cartilage in diseased joints while at the same time supporting its repair.
Adequan Equine works by blocking the destructive enzymes formed in the joint as a result of inflammation while stimulating the production of hyaluronic acid to restore the synovial fluid, and the synthesis of cartilage building compounds.
Apparently, there were over 100 times more recorded outbreaks of equine flu across the UK in 2019 than the year before1, and numerous equestrian events were cancelled as a result.
The company says that despite this, as of 2019, only about half of all UK horses are vaccinated2.
Blaise Scott-Morris MRCVS, Equine Marketing and Technical Manager at MSD Animal Health said: "Last year’s outbreaks of equine flu rocked the equine world, raising important animal welfare issues and costing the racing industry millions.
"Furthermore, they highlighted the need for good preventative healthcare and, in particular, vaccination. It’s vital that more owners are encouraged to vaccinate and those that already have, to keep up with their annual vaccinations and health checks so we don’t experience the same suffering again."
MSD's campaign invites horse owners to join the movement to #fightequineflu, and there is a range of materials to help practices promote the campaign and encourage clients to talk about vaccination and preventative healthcare, including an educational infographic poster, a social media pack and new resources on the Chameleon appointment reminder system.
MSD will itself be promoting the campaign on social media (Facebook: @Keeping Britains Horses Healthy, Instagram: @KeepingHorsesHealthy), and through partnerships with consumer channels such as Horse and Country TV.
There is also a new information resource online at www.kbhh.co.uk/achoo, which offers horse owners links to a range of other educational preventative health materials and horse care advice.
To request your Fight Equine Flu practice pack, speak to your MSD account manager.
Pfizer Animal Health, maker of the equine wormers Equest & Equest Pramox, has launched Stable Mate, a new app to help horse owners manage their daily equine healthcare regime and get maximum enjoyment from their horse.
Pfizer says the new app has been described by testers as 'undoubtedly the best equestrian electronic management system you could wish for'. It includes an organiser in which to keep horses' records and details of their management requirements. It also includes Track My Ride, a GPS mapping and exercise planning service, and a news feed direct from Horse & Hound.
Stable Mate allows users to keep records for up to six horses on their iPhone. They just need to enter the information needed to keep track of each horse's health routine, including worm control, vaccinations, dentistry, farriery and feeding regime. The app then creates a calendar of events, appointments and reminders designed to make it easy for owners to keep their horse's essential healthcare needs on course.
Records can be passed to a yard manager or friends when the owner goes on holiday, making a temporary transfer of care straightforward. Stable Mate also offers general equine health advice, from the essentials of pasture management to understanding vaccination protocols.
Track My Ride is a GPS navigation system that allows owners to map the route, duration and speed of each ride. Pfizer says it's a great device for planning and monitoring exercise programmes, that owners can use it to explore new hacking routes safely and that they'll never have to worry about finding their way back to their horse box again when hunting or doing a long distance ride. Details of each ride are stored in a history log and can be shared with friends through social media.
Paul Blanc, Pfizer's equine brand manager said: "We have tried to develop an app that is all about the horse and their owner, making it as easy as possible for owners to keep their equine health care on track as well as add to the fun and pleasure with their horse. Stable Mate has well and truly surpassed our expectations. We hope that owners and riders find Stable Mate useful and enjoyable."
Stable Mate is currently available only for iPhone with Android and Blackberry coming soon.
Stable Mate is available free from the iPhone App Store http://itunes.apple.com/us/app/stable-mate/id532341393?ls=1&mt=8. To find out more visit www.wormingyourhorse.info.
CEVA Animal Health has produced Understanding sacroiliac disease, a leaflet to help horse owners understand the cause, diagnosis and management of sacroiliac disease.
CEVA says sacroiliac disease can be a particular challenge because although it can occur in isolation it often occurs in addition to other sources of hindlimb lameness. Acute sacroiliac injury is usually a result of trauma, such as a fall, which may cause pelvic rotation or fracture, resulting in hindlimb lameness and sensitivity to palpation of the tubera sacrale soon after injury. With chronic sacroiliac disease there is usually no history of trauma, rather a prolonged history of poor performance.
Understanding sacroiliac disease explains the anatomy of the sacroiliac joint, the clinical signs of the disease, how it is diagnosed, the treatment options and the general prognosis. The leaflet is available to equine vet practices as a useful information source for clients. You can order free copies from your CEVA sales representative.
A research project funded by equine charity The Horse Trust has succeeded in killing equine sarcoid cells in vitro by silencing a gene in the virus that causes sarcoids. The researchers are now hoping to obtain funding for clinical trials using the new technique, which could result in a more effective, non-toxic treatment for sarcoids.
Sarcoids are skin tumors caused by infection with the Bovine Papillomavirus (BPV). They are the most common type of tumour found in horses - the estimated prevalence in the UK is 6-7%. Although the disease is rarely life threatening, many horses with sarcoids are euthanased because the condition is untreatable or because the horse is unsellable. Currently there is no universally effective treatment for sarcoids and if treatment fails the sarcoids will often come back worse.
However, research that was given funding by The Horse Trust offers a potential ray of hope for owners of horses affected by sarcoids. The research was published in Virus Research journal earlier this year.
The research, which was led by Professor Lubna Nasir of the University of Glasgow, found that by inhibiting the activity of a particular viral protein within sarcoid cells, the amount of viral DNA in the cells reduced. This led to a reduction in the growth of the sarcoid cells and caused the cell to die by Programmed cell-death (PCD). The researchers believe that PCD occurs because the sarcoid cells become reliant on the virus.
Professor Nasir said: "This could potentially be a major breakthrough in the treatment of sarcoids. We are now seeking funding to use this technique in clinical trials on horses that have sarcoids."
The research team inhibited the activity of a viral protein called E2, which is needed by BPV to replicate. They used a novel approach termed 'gene silencing' to suppress the activity of the gene that codes the E2 protein. The research was carried out in vitro on fibroblast cells, which had been cultured from sarcoid tissue removed from animals during surgery.
As this research was carried out in vitro, the researchers will now need to see if they can replicate the results in vivo, by developing a way of targeting the sarcoid cells in horses.
"One of the challenges with gene silencing is administering it within clinical setting - as you need to get molecules into every cell. As sarcoids are on the surface of a horse, we think administration should be relatively easy - potentially by injecting or applying a cream to the sarcoid," said Professor Nasir. "If we are able to successfully develop this technique it would be a non-toxic and easy to administer treatment for horses affected by this distressing condition."
Nasir's research could also have an impact on the treatment of lesions in cattle, which are also caused by BPV. Around 50% of cattle in the UK are estimated to have lesions. It may also help with the treatment of Human Papillomavirus (HPV) infections in humans. HPV, which is similar to BPV, can lead to various cancers in humans including cervical and vaginal cancer.
Paul Jepson, Chief Executive and Veterinary Director of The Horse Trust said: "We are really excited that the research we have funded could lead to a major breakthrough in the treatment of sarcoids."
The objectives of the study1 were to assess the impact of the pandemic on the management of laminitis susceptible horses and ponies, to identify challenges faced in implementing COVID-19 based guidance, and to ascertain areas of decision making and policy development which could undergo improvement in future pandemic or emergency scenarios.
Lead author Ashely Ward, a PhD student at SRUC said: "We discovered that lockdown-associated factors had the potential to compromise the welfare of horses and ponies at risk of obesity and laminitis.
“These included: disparate information and guidance, difficulties enacting public health measures in yard environments, and horses having reduced exercise during the pandemic.
"Our conclusion was that guidelines should be developed for the care of horses and ponies at risk through collaborative input from veterinary and welfare experts. This would help to reduce the negative impacts of future lockdown events in the UK.”
Clare Barfoot RNutr, Marketing and Research and Development Director at Spillers said: “This work carries important recommendations to reduce equine welfare risks during any future lockdowns.
“This summer our primary focus has been on helping horse owners keep their horses at a healthy weight to reduce the risks associated with obesity, in particular laminitis. Until formal guidelines are developed we hope our range of practical advice, available online and via our Care-Line will help, should there be another lockdown."
The study was conducted in tandem with research looking at how the challenges brought about by the Covid-19 lockdown affected horse on the human/animal interaction. The conclusion, disseminated by SRUC last week, concluded that the coronavirus pandemic had a negative impact on the mental health and wellbeing of horse owners. https://www.sruc.ac.uk/all-news/horse-power-helps-owners-through-lockdown
Reference
Improve International has announced that the role of Official Veterinarians in animal welfare is the theme of this year's OV Conference, taking place on the 29th & 30th September.
The conference programme includes lecture streams and round-table discussions on themes relating to both Large Animals and Small Animals, in addition to a series of lectures aimed at Equine Practitioners.
This second OV conference is a collaboration between Improve International, which handles OV registration and training in England, Scotland and Wales; 5m Publishing and the Animal and Plant Health Agency (APHA). They say their objectives are to provide a forum to discuss the latest developments in OV work and to offer an opportunity for OVs to network and share experiences and ideas.
Large animal topics to be discussed at the event include Bovine TB, Bluetongue and Porcine Epidemic Diarrhoea while small animal practitioners will focus on export regulations, certification, the Pet Travel Scheme, together with welfare and exotic disease issues. Equine lectures will include legislation updates and welfare and exotic diseases.
An exhibition of the latest products and services of interest to OVs will again run alongside the conference which will take place at the Alexandra House Hotel and Conference Centre, near Swindon, where Improve International is based.
David Babington MRCVS, Managing Director of Improve, said: "The enthusiastic discussions following many of the lectures at our first conference and the resoundingly positive feedback we received from the 250 delegates attending convinced us of the value of a forum that brings OVs together with experts from private practice, other animal health-related organisations and the APHA.
"Animal welfare is a particularly important topic for OVs so it is the theme for this year's event and all of the speakers will address it within the context of their lectures. We look forward to, once again, welcoming OVs from across the country to Alexandra House in September 2016."
For more information on the Official Veterinarian Conference and Exhibition or to register visit: www.officialvet.com
Petplan Equine is now seeking nominations for the Equine Vet of the Year Award 2009, an award to recognise vets that go above and beyond with their care of horses and their owners.
Andrew Dobson of The Barn Equine and Large Animal Practice in Great Wakering, Essex, is the current 2008 Equine of the Year. He was nominated by a number of his grateful clients and their glowing testimonials impressed the judges enough to give him the edge over his closest rivals for the title.
The 37 year old qualified in 1999 and for the last four and a half years has run his own practice. His involvement with horses evolved from a desire to work with large animals and the outdoor life it would bring.
Andrew said: "I was absolutely stunned. I'm so honoured and amazed to have received the Petplan Equine Vet of the Year award. I really enjoy what I do and would like thank all my clients, Petplan Equine and The Animal Health Trust for their support."
If you feel you know a vet that displays equine clinical excellence and fantastic customer care you can nominate online by visiting www.petplanequine.co.uk/events Nominations close 3rd October 2009. An independent panel will judge the nominations and the winning vet will be announced at the Animal Health Trust UK Equestrian Awards in London, in November 2009.
Despite being a common disease, CVS says very little research has been undertaken into EPD in the UK.
In addition, numerous different treatments are currently used for EPD, for which there is not always robust scientific evidence.
The CVS study, which started in 2022 and will continue till early 2024, involves 20 practices.
Samples have been collected from over 70 cases from horses that have been diagnosed by EPD throughout the UK.
Full blood profiles have been assessed, in addition to bacterial culture analysis of the lesions, PCR analysis for dermatophytes (ringworm fungi), microscopy for ectoparasites (mites) and skin cytology.
An owner questionnaire has also been completed to gather information on EDP management.
Each horse’s lesions have been graded and descriptive data relating to the lesions were recorded.
Data collection is now complete and a team of researchers, led by vet Manuela Diaz Ramos, has started analysing the data.
A full report on the findings, along with treatment and management recommendations, is expected to be presented at a scientific conference later this year.
The company points to research which found that 89% of the veterinary profession wants to play a more active role in the sustainability agenda1.
For that reason, Boehringer says it put sustainability at the heart of Aservo EquiHaler, which uses no propellant gasses and the container for which is made from up to 50% recycled materials.
Now Boehringer has launched the first recycling programme for a prescription medicine in the UK to support the responsible disposal of the Aservo EquiHaler.
To join the programme, you need to visit: https://equihaler.uk/recycling, set up a TerraCycle account and register your practice. Boehringer says it only takes 10 minutes.
Once signed-up, a Boehringer Ingelheim Territory Manager will arrange for a collection box to be delivered, along with supporting practice display posters. When the box is full, there is a free pick-up service.
Practices that sign-up for the programme before 31st July 2021 will be entered into a prize draw, with the chance to win a year’s supply of ethically-sourced chocolate for their practice.
Reference:
New research, conducted by the WALTHAM-initiated Laminitis Consortium, has raised questions over the assumption that soaking hay will make it safe to feed to laminitis-prone horses and ponies1.
The Laminitis Consortium comprises world-leading equine veterinary, nutrition and research experts interested in collaborating on the important topic of laminitis. It includes the authors of this work: Dr Pat Harris of the WALTHAM® Equine Studies Group, Clare Barfoot of Mars Horsecare UK Ltd and Dr Annette Longland of Equine Livestock and Nutrition Services (ELNS).
Over-consumption of water-soluble carbohydrates (WSC) has been associated with the onset of laminitis. It has been recommended that hay with a non-structural carbohydrate (WSC and starch) content of less than 10% should be fed to obese animals as well as those at risk of laminitis2 and that hay should be soaked in water before being fed in order to reduce the WSC3,4,5. The study, which was completed earlier this year, examined the loss of water-soluble carbohydrates from nine different hays submerged in water for up to 16 hours. It was presented to the biannual Equine Science Symposium in America in May 2009.
Previous studies have shown that the prolonged soaking of chopped hay in large volumes of water can result in the leaching of nutrients, including soluble carbohydrates. However, because common practice in the UK tends to involve long-stemmed hay, soaked in relatively small volumes of water over varying timescales, the Laminitis Consortium's study aimed to replicate such a practice6.
The nine different hay samples were analysed for WSC and then soaked in cold water. The soaked samples were subsequently analysed at four intervals of 20 minutes, 40 minutes, three hours and 16 hours.
Clare Barfoot said: "The results showed a highly variable leaching of WSC and substantially less leaching than reported previously for chopped hay soaked for 30 minutes.3
"Very few samples reached below 10% WSC, despite prolonged soaking. The concern is that this strongly suggests that soaking may not be sufficient to render some hays safe to feed to horses and ponies prone to laminitis.
"Our current advice is that ideally you should analyse your hay before feeding it to an animal at high risk of laminitis and choose hay with the lowest WSC content you can find. Soaking hay provides an additional safeguard but should not be relied upon."
The study also highlights that if hay is soaked for extended periods, it may not meet the nutritional requirements of the animal because substantial amounts of other nutrients, protein, vitamins and minerals will also be lost 5. In such cases it is even more important that the horse or pony should receive a balanced supplementary feed.
The Laminitis Consortium is continuing its work in this area and hopes to be able to identify practices that will be of greater benefit to the horse owner faced with hay of unknown WSC content.
1Longland AC Barfoot C & Harris PA (2009) The loss of water- soluble carbohydrate and soluble protein from nine different hays soaked in water for up to 16 hours. J. Equine Vet Science 29 (5 ) p 383 - 384, 2 Frank N Equine Metabolic Syndrome J Equine Vet Sci 29 (5) p 259 - 267, 3Cottrell, E., Watts, K., Duarte, S. and Ralston, S. (2005). Equine Science Symposium, 2005, 4Kenny, D. (2007). Proceedings of the British Society of Animal Science. 5Warr EM, Petch JL. Equine Vet Educ 1993;5:169-171, 6Longland, A.C. (2009) In preparation.
CEVA Animal Health has produced a leaflet to help horse owners understand the diagnosis and treatment of navicular disease.
Navicular disease can be difficult to diagnose and management of the condition can be a challenge for both vets and horse owners. The new leaflet helps owners get to grips with all aspects of the disease from the clinical signs to the procedures used to obtain a formal diagnosis. It then covers the various treatment options available including corrective farriery, analgesia, bisphosphonates and surgery. Diagrams and photographs help to ensure that the information is clear, concise and easy to follow.
The leaflet is available to equine vet practices as a useful information source for clients. Please order your free copies from your CEVA sales representative.
The RCVS and the Veterinary Medicines Directorate (VMD) will be holding a free Masterclass offering practical guidance on the requirements of the Veterinary Practice Premises Register, on Saturday 4 April, at BSAVA Congress.
If you are concerned about medicines inspections and would like further information about complying, this is your chance to find out what you need to do.
By 1 April, all practice premises from which medicines are supplied should be registered with the RCVS. All such premises are then subject to inspection - by either Practice Standards Scheme inspectors, if accredited under the Scheme, or VMD inspectors. Will you be ready if an inspector calls?
Suitable for veterinary surgeons, veterinary nurses and practice managers, the interactive session will be held from 10am - 12noon, with presentations from VMD and the Chief Inspector of the Practice Standards Scheme, followed by group discussion and plenty of time for questions and answers.
Attendance at the Masterclass, which will be held in Hall 6 of the ICC in Birmingham, is free to BSAVA passholders.
For your free ticket, contact Fiona Harcourt on 020 7202 0773, f.harcourt@rcvs.org.uk, or during Congress visit the RCVS Stand, number 918, opposite the catering stand in the Exhibition hall.
Dechra Veterinary Products, manufacturer and distributor of Equipalazone®, has launched a new website with up-to-date advice and guidance on the subject of equine pain management for horse owners: http://www.equinepainmatters.com/
Dechra says the website offers owners a place to go for information about pain in their horse including causes, diagnosis and the tools and techniques that their vet may use to treat pain. Owners will also be able to download anatomy charts and information leaflets on topics such as pain management, lameness, anaesthesia, sedation, euthanasia, the importance of microchipping and wound management.
Larry King, equine product manager at Dechra said: "This website is great for horse owners as they now have one place to go for information about equine pain matters. It will help them gain a better understanding of managing pain in their horses and the critical role that their vet plays in this area. Veterinary practices can also refer owners to it to support their consultation. This is the first website to put all this information together, so we are sure it will be popular.
"Cards with the new website address are available for practices to hand out to clients. "The website allows clients to browse the site in the comfort of their own home and is also ideal for practices with limited storage space for client information materials."
Dechra also encourages practices that have their own websites to link directly to www.equinepainmatters.com. Practices can order hand-out cards by contacting Dechra on 01743 441632 or email marketing@dechra.com.
Super early bird tickets are available till 28th May.
Rose’s programme recommendations are:
BEVA Congress programme will be embracing the overarching theme of “use it wisely or lose it forever”, chosen by BEVA President Bruce Bladon.
Bruce said: “Antibiotics is an issue which goes so far beyond equine practice and is one of the genuine threats to humanity.
"We must use these precious and finite resource wisely, or, quite reasonably, regulators will prevent us having access to them.
“But this theme resonates further, to the “social licence” which threatens the future of equine sport.
"Rather than platitudes about horse welfare, we now need to show the positive steps we can take to minimise equine injury.
"We need to be developing screening programmes and to be instrumental in safety programmes.
"Otherwise, we may lose equestrian sport forever.”
Individual super early bird BEVA members prices for a three-day pass are £539 for vets for all three days (with concessionary available for those in their first three years of graduation or earning less than £25,000).
Day tickets and practice passes are also available.
Super early bird ends on 28 May 2025.
http://www.bevacongress.org
Academics from the University of Bristol's School of Veterinary Sciences and the neurology team at Southmead Hospital Bristol have published the results of study examining the use of percutaneous electrical nerve stimulation (PENS) therapy as a treatment for headshaking syndrome in horses.
The authors say that the condition, a neuropathic facial pain syndrome, often leaves affected horses impossible to ride and dangerous to handle, and can result in euthanasia. At present there are no consistently safe and effective methods for the treatment of headshaking in horses, and the condition is estimated to affect between 10,000 and 20,000 horses in the UK.
The study, which is published in the Equine Veterinary Journal (EVJ), aimed to discover whether PENS therapy, developed by Algotec Research and Development Ltd, is safe, effective and sustainable for the management of trigeminal-mediated headshaking in horses.
Seven horses diagnosed with trigeminal-mediated headshaking were recruited to the trial. All procedures were carried out in sedated horses with a needle-prick sized area of skin desensitised with local anaesthetic to help probe insertion. A disposable PENS probe was placed just beneath the skin adjacent to the nerve under ultrasonographic guidance. The nerve was stimulated for 25 minutes following a protocol of alternating frequencies and a perception threshold based on human clinical data. The probe was removed and the procedure repeated on the other side. Three or four treatments were used during the protocol, with treatments being repeated when signs of headshaking recurred.
All horses tolerated the procedure well. Three horses developed a haematoma at the site on one occasion and two had increased clinical signs for up to three days following first treatment. Six horses responded well after the first treatment and returned to ridden work at the same level before headshaking began. Five horses continued to respond to further treatment.
Veronica Roberts, Senior Clinical Fellow in Equine Medicine in the University's School of Veterinary Sciences, who led the study, said: "Headshaking in horses is a major welfare issue and can be a significant cause of distress.
"Although it is clear that further work is required, including increasing the number of cases and refining the treatment procedures, the study shows that PENS therapy should be the first-line treatment for trigeminal-mediated headshakers, which have failed to respond to conservative treatment, such as nose-nets."
B&W Equine Group has opened a brand new, state-of-the-art equine clinic at Breadstone in Gloucestershire.
The new facility opened on 1 October 2011. It cost over £2.2 million and is, according to the company, one Europe’s most advanced diagnostic and surgical centres.
B&W Equine Group was created in 2008, following a merger between Willesley Equine Clinic and Bushy Equine Vets. The 23 vet practice has four local equine clinics in Breadstone, Cardiff, Failand and Willesley.
The new clinic, located on a four acre site at Breadstone, close to the M4 and M5 intersections, provides state-of-the-art diagnostics and advanced laboratory facilities. It houses the only equine MRI scanner in Wales and the South West, as well as a CT scanner and scintigraphy unit. Orthopaedic and colic theatres, adult and neonatal intensive care suites and separate isolation units have all been custom-designed and are supported by five examination rooms and two knock down boxes.
Clinical and referral services are led by RCVS and European Recognised Specialists in surgery, orthopaedics, diagnostic imaging and internal medicine and include gynaecological management of breeding mares and pre-season disease screening. The on-site laboratory is one of only 30 in the UK to be certified by the HBLB to test for CEM and EVA.
Ian Camm, BVSc CertEP MRCVS, Group Director, said: “We are all extremely excited about the new clinic but our day-to-day first opinion work remains a top priority. For all our local clients it’s very much a case of business as usual but the fact that we have invested in the latest portable equipment, including video endoscopes, digital radiography and ultrasound scanners, means we can undertake more specialist work at client’s yards, as and when needed.”
For further information, visit www.bwequinevets.co.uk.
The Society for Practising Veterinary Surgeons (SPVS) has published its 2015 Fee Survey, which has revealed an increasing divergence between fees charged for routine and unroutine procedures in small animal practice.
SPVS says that small animal practices accounted for the largest proportion of responses to its survey, and that 75.9% of them had increased their fees during the last 12 months. When comparing a 'bundle' price comprising a kitten vaccination course, puppy vaccination course, cat spay, dog spay and consultation, the increase was 4.09%. However SPVS notes that this increase may be artificially low, as it relates to the sort of procedures that are regularly quoted and may therefore be constrained by the marketplace.
Perhaps more revealingly, whilst routine procedures such as vaccination had risen 3.3%, non routine procedures had risen by considerably more: pyometras were up 15.6%, cat dentals were up 17.5% and out-of-hours callouts were up 18.6%.
Equine fees showed an overall drop of 3.5% on the bundle price comprising initial routine examination, five-stage PPE, routine dental examination and float, a colic examination and the cost of sedation / waiting. Although many of the individual equine procedures showed a fee decrease, 79% of equine practices reported that they had increased fees over the past year. The largest decrease in equine fees was for sedating a horse and waiting while the horse was clipped or treated by an equine dental technician, with the fee charged being 12.5% less than last year and ranging from £12.50 to £93.82. Conversely, conducting an ultrasound scan of a mare for pregnancy had increased by 17.3% and ranged from £20 to £62.36.
For large animal vets, the fees are more tightly constrained by the commercial realities of farming and the range of fees quoted tends to be lower. This year, the overall price rise for the bundle of fees comprising routine calving, foot trimming, elective Caesarean and hourly rates for fertility work and herd health schemes was 4.1%. However, only 47.8% of large animal practices reported an increase in fees charged over the last twelve months. The largest increase reported was for paring the hind feet of a cow without sedation, which was up 24.4% and ranged in price from £19 to £70, while issuing a prescription to a farm animal client had decreased by 1.6% and ranged in price from 0 to £48.
Nick Stuart, SPVS president said: "We all know the industry is facing real challenges and this is reflected in the fee survey, with equine practices in particular decreasing many of their prices on last year. However the survey also shows that the fees vets charge vary widely, particularly in the small animal sector. While some of this can be accounted for by differing overheads, it does provide a fascinating insight into the various financial models that exist and challenges practice owners to review how they construct their fees. It also suggests that there is scope for practices to grow their profitability and understanding the market will help them with this.
"We have a new benchmarking service from Veterinary Insights that will help practices to set more accurate fee levels and we will be developing our fee survey further so that it dovetails with this service. I would urge practices to join SPVS and access the invaluable data we produce to help them grow their businesses."
For more information, a copy of the survey, or to join SPVS visit www.spvs.org.uk
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.
The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.
Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.
Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.
Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.
CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/
Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial
Reference M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x